*2.3. Inhibition of Collagen Deposition*

The main clinical feature of liver fibrosis is the excessive deposition of ECM, particularly collagen. Collagen I is the main component in ECM, and the cross-linking of collagen I is significantly increased in liver fibrosis. Therefore, collagen I reduction has been adopted to treat liver fibrosis. In one study, the monoclonal antibody AB0023, which is an inhibitor of the matrix remodeling enzyme LOXL2, inhibited liver fibrosis by regulating the cross-linking of collagen I [52]. In another study, the human monoclonal antibody GS-6624 was used for the treatment of NASH-induced liver fibrosis [11].
